www.publiscripts.com SPONSORED BY

Continuous subcutaneous insulin infusion (CSII), more commonly known asinsulin pump therapy, delivers rapid acting insulin subcutaneously, in a flexi-ble and precisely controlled manner via a programmable pager sized device with an insulin reservoir. Basal insulin delivery rates can be varied according to the time of day, and during periods of exercise. A patient (or parent)-initiated bolus of insulin can be delivered in a variety of profiles aimed to match the nature of the ingest-ed meal. Relative to the more widely used modality for delivering insulin, multiple daily injection (MDI), CSII allows for more accurate delivery, reduced variability in insulin absorption, and greater flexibility with both basal and bolus insulin delivery. While CSII offers a larger number of options with regard to insulin dosing, the quali-ty of any decisions made with regard to adjustments in patient management will be in part dependent upon the quality and completeness of the information upon which these decisions are based. Glucometer readings obtained from finger prick testing for intermittent self-monitoring of blood glucose (SMBG) is at present the most widely used method employed by patients for monitoring their glucose levels at home. They INFUSYSTEMS ASI